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Abstract
Background: South Africa has the largest prevalence of HIV infection. This epidemic impacts
adults as well as the pediatric population. The presence of drug-resistant mutations to
antiretroviral therapies among infants and children is on the rise. Few studies have been
conducted on this topic.
Objective: The study aims to determine whether drug resistance testing in the form of genotypic
testing is cost-effective when deciding whether to switch to a new HIV antiretroviral therapy
following drug failure.
Method: An interactive research approach is taken by collecting primary data from experts in this
field. Secondary sources including guidelines from the World Health Organization and the South
African Department of Health were also analyzed.
Results: This study finds that, at the moment, genotypic testing is not cost-effective and should
not be employed in routine primary care clinics.
Conclusion: Although not recommended for routine care, genotypic testing is extremely
beneficial when determining the underlining cause of drug resistance and when tailoring
individual regimens for patients. A scale-up of the HIV response and a low-cost drug resistance
test are needed in order to make it cost-effective.
Key Words: HIV drug resistance, genotypic testing, pediatric, South Africa
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Preface
The topic of HIV/AIDS in Sub
Sub-Saharan Africa is large and multi-faceted.
faceted. There is an
abundance of existing research available on the causes and determining factors of HIV, along
with the biological progression of this virus and the progression as a worldwid
worldwidee epidemic.
However, the topic of HIV drug resistance among pediatric populations has
as had less focus.
My future goal of working in the health sector with the Peace Corps in a French-speaking
French
African country fueled my initial interest in HIV infection in Africa. My interests grew
throughout my studies with the School for International Training in Nyon, Switzerland. On
September 15, 2014 a presentation was given at UNITAIDS by Mrs. Gelise McCullough. This
presentation outlined the market limitations of ped
pediatric
iatric antiretroviral therapies along with the
wide treatment gap which exists. This debriefing was a key influence in the selection of the topic
for this research study. Specifically, I was interested in the stories of young children needing to
go on second and third-line
line therapies due to HIV drug resistance. It struck me as a major
problem which must be addressed. The selection to focus on South Africa came during research
when I learned that this country has the highest prevalence of HIV infection. I then
the became
curious as to what this middle-income
income country can do to prevent HIV drug resistance among
children and whether genotypic testing could be a cost
cost-effective tool.
Many experts in this field, including those who participated in this study, provided advice
throughout the research and writing period. Advice included how to break this topic into chapters
and how to approach writing a lengthy research paper. Overall the process of reaching out to
experts and securing personal interviews vastly improved m
my
y skills as a researcher and academic.

19/11/14
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Introduction
By the end of 2010, there were an estimated 34 million people globally living with
HIV/AIDS, a 17% increase from 2001. Of this, 3.4 million are children where 91% of the
infected are living in Sub-Saharan Africa (UNAIDS Data Tables, 2011). The increase in
prevalence is due largely in part to the improvements in the quantity and quality of antiretroviral
(ARV) therapies available, as well as the rollout of these treatments in low and middle income
countries. While there have been significant advances in HIV treatments and surveillance
programs for adults, there remain many obstacles towards achieving parallel success among
children infected with HIV. By the end of 2012, an estimated 220,000 South Africa children
were in need of antiretroviral therapy (ART) (Antiretroviral Therapy for HIV Infection in Infants
and Children, 2010). Efforts have been undertaken by several organizations such as the Joint
United Nations Program on HIV/AIDS (UNAIDS), the World Health Organization (WHO) with
UNITAIDS, and the Clinton Health Access Initiative (CHAI) towards closing the treatment gap
among children. Specific focus has been on improving the market limitations such as cost and
availability. Concern for ART in regards to children is exacerbated by the increasing HIV drug
resistance. Drug resistance is attributed to many factors including difficulty with therapy
adherence and drug absorption along with lack of appropriate viral monitoring systems. These
issues are highly prevalent in resource-poor settings such as South Africa. With the limited
treatment options available, choosing the correct second-line therapy is critical, yet resistance
testing is not readily available country-wide (Zanoni et al., 2012). This study attempts to address
the issue of increasing HIV drug resistance among children in South Africa, highlight the South
African national response, and explore the methods taken by the international community to
prevent drug resistance.

Hendrix 6

A substantial field of knowledge exists regarding HIV drug resistance among adults, yet
there are significantly fewer studies which focus on children. Additionally, HIV treatment for
children is vastly different from adults. Challenges exist in the improvement of pediatric ARVs,
mainly the fragmentation of the pediatric market. While many ARVs are circulating the market,
few have been approved for children. For example, although the drug tenofovir (TDF) has been
approved for first-line treatment in adults, there is limited data on the safety of this drug for
children; thus, there are no pediatric formulations with TDF to date (Antiretroviral Therapy for
HIV Infection in Infants and Children, 2010). There is a dire need for safe, palatable, potent,
heat-stable, and fixed-dosed combinations (FDCs) that can be employed in the fight against
pediatric HIV (International AIDS Society, 2013). Finally, there is no consensus as to whether
drug resistance testing upon surveillance of first-line HIV drug failure is cost-effective for
children. The question in focus is whether widespread pediatric drug resistance testing is
efficient when determining whether to switch from first-line to second-line therapies or not.

Literary Review
Drug resistance is an evolving field with new studies continually being released on the
efficacy of first-line and second-line treatments as well as the implementation of strategies to
reduce drug resistance. One approach is to implement resistance testing to detect virological
failure. Most commonly used is genotypic resistance testing, which can detect from a blood
sample mutations in the HIV virus known to cause resistance to certain ARVs. It is currently
being debated whether genotypic testing is cost-effective and whether it should be implemented
in routine care. Three studies represent the competing viewpoints on this issue.
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A study published in 2012 by Levinson et al. reported on the clinical and financial impact
on genotypic testing at first-line ART failure. By using the Cost-Effectiveness of Preventing
AIDS Complications International model of HIV, the researchers were able to simulate a South
African cohort of HIV-positive adults failing first-line treatment. Their findings suggest that
when an individual test cost less than $100 USD, genotype testing becomes extremely costsaving at a rate of $900 per years of life saved by treatment. However, this efficiency is
dependent upon a rate of wild type HIV near 12% and timely results. Their rationale is that
without genotypic testing, virological failure prompting a switch to second-line treatment is
based on CD4 count. However, patients failing ART with wild type virus often have poor
adherence rather than drug resistance. Genotypic testing may distinguish patients with true
resistant HIV from those who might benefit better from adherence counseling rather than a
switch to expensive second-line therapy (Levison et al., 2013). It is important to note that this
simulation was for South African adults rather than children. It is plausible that genotypic testing
is not as cost-effective in children.
A 10-year review of the patterns of HIV drug resistance in South Africa conducted by
Kiepiela et al. concluded that genotype testing is cost-saving for those failing second-line
treatments and cost-neutral for those failing first-line treatments. Due to the results, the
researchers suggested that this testing be included in routine care (2014). A possible reason for
the neutrality among patients failing first-line is that second-line treatments are becoming more
affordable and it may or may not be worth waiting to switch treatments until test results are
analyzed. There are several benefits of genotype testing proposed by Lessells et al. in 2013
including most importantly identifying the root cause of virological failure such as poor
adherence, interruption of therapy, or poor absorption of the medications (2013).
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The final viewpoint is that genotypic testing is not cost-effective. In October 2014,
Phillips et al. reported that despite the assumptions of a relatively inexpensive process, resistance
testing at first-line failure when deciding whether to switch to second-line therapy was not costeffective. They used a similar method as Levinson et al. by simulating a model of HIV
progression and the effects of ART in a low-income setting. Patients with virological failure but
no resistant mutations have better outcomes when they switch to second-line treatment rather
than not, because it is extremely hard to change patterns of adherence. In addition, second-line
therapies are more forgiving of weaker adherence due to their higher potency (Phillips et al.,
2014). A major argument against implementing widespread HIV drug resistance testing in lowincome settings is that clinical and institutional infrastructures are already weak. Priority in
regards to funds, human resources, and technology should be directed towards testing for the
infection and providing treatments.
After a review of this literature, it is clear that there is a lack of consensus regarding the
cost-benefit factor of genotypic resistance testing among children providing a rationale for this
study.

Research Methodology
In order to answer the research question, primary and secondary sources were gathered
using a variety of methods. For secondary sources, a search was conducted on databases such as
PubMed, Google Scholar, and Web of Science with the key words “HIV drug resistance”,
“Children”, and “South Africa”. These searches revealed many studies conducted on these topics
as well as government documents. Two main documents discovered were the “Consolidated
Guidelines on the use of ARV Drugs for Treating and Preventing HIV Infection June 2013”
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published by WHO and the “South African Antiretroviral Treatment Guidelines 2013” published
by South Africa’s Department of Health. A comparison was made to determine whether drug
therapies in South Africa follow the guidelines of WHO. Primary sources include the personal
interviews conducted by the researcher with various experts in the field of HIV drug resistance.
Interviewees were first contacted by email to determine whether they were available to
participate. These emails contained detailed information including the purpose of the study along
with a request for participation by means of an interview ranging from 30 minutes to one hour.
A combination of methods was employed to collect the data, but it was mainly a
qualitative approach. The researcher started with observations of the problem, HIV drug
resistance among children, and formulated a theory about drug resistance testing from the
findings. Interviews were semi-structured in that questions were prepared ahead of time, but the
participants were encouraged to take the conversation in different directions so that it was a
natural process. In addition, the process of drug resistance was interpreted from the participant’s
perspective. Although this is a case study of country, it is the researcher’s hope that a theoretical
generalization can be made with the results so that they can be applicable to not only South
Africa but other low and middle-income countries.
All ethical considerations were taken in this study. No harm was inflicted on the research
participants and each was given a detailed description of the research prior to involvement.
Confidentiality and privacy were ensured by gaining informed consent to use interviewees’
names and other identifiable information. Consent was also given before notes were taken.
Interviewees had the opportunity to not answer a question or to stop the interview at any time.
Special consideration was taken since this study was focused on one country. Information was
gathered and analyzed on South Africa strictly for educational purposes without the intent of
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embarrassment. Finally, children are a vulnerable population. Although the topic is HIV drug
resistance among children, none were used as participants in this research.

Analysis
Pediatric HIV in South Africa
Overall, South Africa has a generalized HIV epidemic, with greater than one percent of
the population infected. Although the epidemic has stabilized over recent years, the prevalence
rate is still extremely high, at around 19.1% for adults aged 15 to 49 years. Compared to this
alarmingly high level, the pediatric prevalence rate among those aged 0 to 14 years was only 2.4
percent in 2012 (Human Sciences Research Council, 2014). However, there is a wide treatment
gap among that 2.4 percent living with HIV. In Sub-Saharan Africa, a region accounting for 91%
of the global pediatric treatment need, coverage is extremely low at around 21% (UNAIDS Data
Tables, 2011). With the 2013 estimates now at 360,000 South Africa children living with HIV,
there is a clear motivation to provide the necessary treatment (HIV and AIDS estimates, 2012).
PMTCT Strategies
In the last decade, there have been strong efforts in South Africa to prevent mother-tochild transmission (PMTCT). These practices include primary prevention of transmission,
prevention of unintended pregnancies, and equitable access to testing, counselling, and ART
(Global guidance on criteria, 2014). In 2002, the South African Department of Health launched
national PMTCT programs. Policies have been revised several times with new provisions
including a shift towards an increase in infant HIV testing at an earlier age (Barron et al., 2013).
At inception of the program, single-dose nevirapine was used as the standard of PMTCT
maternal care in South Africa. However, this therapy is strongly associated with non-nucleoside
reverse transcriptase inhibitor (NNRTI) resistance among HIV-infected infants. When the WHO
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recommended combination regimens for these programs in 2006, South Africa scaled up its
standards to include these new regimens.
Overall, there has been an evolution in PMTCT strategies to shift towards earlier
treatment. Now the preferred therapy for mothers, Option B+ suggests that all pregnant and
breastfeeding women with HIV start ART immediately after diagnosis and maintain their therapy
for the duration of the mother-to-child transmission risk (Consolidated Guidelines, 2013).
PMTCT efficacy is strongly dependent on how quickly the mother is diagnosed, whether she
continues treatment after birth, and how quickly the infant is tested (G. McCullough, personal
communication, October 30, 2014). For these reasons, WHO has identified early identification of
HIV-infected children as vital for PMTCT success. When proper PMTCT methods are
employed, HIV transmission to the infant is reduced from 35% to about 2 – 20% (Antiretroviral
Therapy for HIV Infection in Infants and Children, 2010). By reducing the viral load to
undetectable levels in the infected individual, risk of transmission is significantly reduced.
The new PMTCT strategies dramatically reduce the number of children who acquire
infection, but among those who do become infected, NNRTI resistance prevalence is high. A
study conducted in 2011 in Johannesburg, South Africa included 230 recently infected HIVpositive children under the age of two. Two-thirds of the participants had been exposed to either
maternal and/or infant PMTCT. Of those exposed, 56.8% had NNRTI mutations while 14.8%
had nucleoside reverse transcriptase inhibitor (NRTI) mutations (Kuhn et al., 2014). One
wonders how problems with adherence play a role in the presentation of resistant mutations and
whether what drug resistance testing in this study would have revealed.
Finally, with a focus on 22 priority countries including South Africa, WHO created a
Global Plan towards the elimination of new HIV infections among children. The goal is to
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“reduce the number of new HIV infections among children by 90%” and to reduce the rate of
mother-to-child transmission to less than 5% (Global guidance on criteria, 2014). There is a
clear need to address the millions of infected children so that they can live normal lives, but it
also just as important to prevent children from getting infected.
Pediatric HIV Drug Resistance
With the increased access and exposure to ART, the number of infants and children with
HIV drug resistance (HIVDR) is on the rise. The study “Pediatric Response to Second-Line
Antiretroviral Therapy in South Africa” found that 9.1% of the 880 children involved
experienced drug failure to their first-line therapy after a median time of 95 weeks (Zanoni et al.,
2012). Since ART is a lifetime treatment, it is alarming that this many children needed to switch
regimens so soon after treatment initiation. The cost and pill burden is high for these children
requiring second-line treatment, and their therapy options are dramatically limited.
HIVDR among children can result in two ways. Transmitted drug resistance, or TDR,
occurs when a drug-resistant strain is spread from mother to infant (Antiretroviral Therapy for
HIV Infection in Infants and Children, 2010). A study conducted between 2005 and 2009
suggests that TDR rates vary among South African provinces. The KwaZulu-Natal province has
the highest rates with up to 15% of transmitted resistance to the NNRTI drug class (Hunt et al.,
2012). These high rates are contrasted with the prevalence in the Western Cape Province at 3.8%
(South African National AIDS Council, 2011). This increases the difficulty in universalizing
treatment procedures across South Africa.
The other source of HIVDR is acquired drug resistance or ADR. ADR occurs when
mutations of the viral genetic code appear following administration of pediatric ART. The HIV
virus replicates so quickly that mutations in the genetic composition render the antiretroviral
drugs ineffective against those mutated strains. This type of resistance among children is most
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commonly attributed to poor adherence, use of suboptimal treatments, or to toxicity and
absorption issues. Several studies support the notion that poor adherence to ARTs is a social
predictor of virological failure, defined by WHO as a “plasma viral load above 1000 copies/ml
based on two consecutive viral load measurements” separated by 3 months of treatment (Barth et
al., 2011 & Consolidated Guidelines, 2013). Due to the rapid replication of this retrovirus and
longevity of treatment plans, mutations will occur, even among those who follow therapy
regimens perfectly. In addition there is also the issue that drug resistance can develop at any
stage of treatment. Multidrug resistance among children who have taken multiple ART is
increasing (Antiretroviral Therapy for HIV Infection in Infants and Children, 2010). With the
limited data available, there is little to base national recommendations regarding treatment plans.
Types of HIV Drug Treatments
Among the therapies available are the three classes of antiretroviral drugs including
NRTI, NNRTI, and protease inhibitors (PI). In 2013, the WHO updated the Optimal
Formulatory List for pediatric HIV medications. This list includes ten drugs with their drug class,
suggested formulation, and dosage (UNICEF, 2014). Although a consolidated list simplifies the
decision of which ARTs to use, it also limits the options available once a treatment becomes
ineffective. Among the NRTIs, the only drug listed by itself as optimal is a thymidine analogue
named zidovudine or AZT. This drug is generally well-tolerated among children but has been
linked to metabolic complications such as anemia. The other thymidine analogue stavudine or
d4T is associated with lactic acidosis and therefore, has been phased out of use since 2010. Two
other NRTIs are used among children but are found in fixed-dosed combinations, that is, they are
mixed with other drugs to make appropriate formulations for children. Optimal combinations
include those of AZT with lamivudine (3TC), a cytidine analogue with a strong safety and
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tolerability record, and those of AZT and abacavir (ABC) (Antiretroviral Therapy for HIV
Infection in Infants and Children, 2010).
For the NNRTI drug class, the two optimal medications are efavirenz (EFV) and
nevirapine (NVP), both often found in FDCs. The final drug class, the PIs, operate by inhibiting
the activity of protease, an enzyme used by the HIV during the production of new viral
components. The only optimal PI is ritonavir-boosted lopinavir (LPV/r). While LPV/r is
regarded as the most appropriate regimen for infants, it is poorly adapted for children in that it is
only available in liquid form, has high alcohol content, and is heat sensitive requiring
refrigeration (Better HIV Treatment for Infants, n.d.).
The difficulties in choosing a medication go beyond possible side effects and toxicity.
When picking among a drug class, such as the NRTIs, the first-line choice impacts the
availability of drugs that can be used for second-line, should the child need to switch. For
instance, since both AZT and d4T are thymidine analogues, failure of either results in the
replication of thymidine analogue mutations (TAMs). When multiple TAMs accumulate, the
functionality of other drugs as second-line therapies such as ABC is reduced. On the contrary, a
child who becomes resistant to ABC on first-line will not have any TAMs and has the option to
take AZT or d4T as second-line (Antiretroviral Therapy for HIV Infection in Infants and
Children, 2010).
Challenges with Pediatric HIV Care
There are many social and physical challenges to providing the correct care for HIV
positive children and ensuring they adhere to their regimens. In South Africa, as in other SubSaharan countries, there is a significant lack of human resources. At the forefront is the shortage
of staff adequately trained to manage HIV (Meyers et al., 2007). This ultimately leads to the
inability to diagnosis and treat children correctly. In this country, around 15% of public health-
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care facilities are unable to initiate HIV treatment (Barron et al., 2013). Doctors in these areas
must refer patients to other facilities, subsequently increasing the complications for the mother in
regards to access to treatment. Currently, there is a lack of good diagnostics with HIV
surveillance and monitoring. Improving diagnostic systems is crucial, because when a mother is
monitored, health officials can ensure that the child is receiving the correct dosing at the right
times.
Other physical factors include limitations in the market for pediatric HIV formulations.
The consistent consumption of necessary medication is hindered by the “poor palatability, high
pill burden or liquid volume, frequent dosing requirements, dietary restrictions and side-effects”
that accompany the available medications (Antiretroviral Therapy for HIV Infection in Infants
and Children, 2010, p.78). In addition, formulation is dependent on weight. In settings where
resources are limited, caregivers try methods such as halving the dose of adults, yet this is
dangerous, because the actual dosage is unknown.
In a series of workshops held in the provinces of KwaZulu-Natal and Gauteng during
November 2012, parents and caregivers of children receiving ART identified the main
challenges in adhering to medications. One challenge was not understanding the need for taking
ART or how to properly administer the regimens. The financing of attending hospitals and other
care facilities also greatly affected access to ARVs. Additionally, several parents had difficulty
obtaining their child’s birth certificate or proving legal guardianship so they could not receive
state aid. Final barriers include frequent appointments and lack of confidentiality among health
care workers (Ngobeni-Allen et al., 2013). All of these factors expose the need for an integrated
health system among the government and care facilities, trained professionals, and adequate
resources.
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Not only are their problems with human and diagnostic resources, but there are also
social factors contributing to the challenges in pediatric HIV care. In many circumstances, the
mother is aware of the positive status of her child but disclosing this information to her husband
would create many problems within the home. In addition, due to the stigma, discrimination, and
anxiety surrounding a diagnosis of HIV, many mothers chose not to disclose the status of their
child to their friends or community. As a Technical Director for UNITAID, Gelise McCullough
travels to countries to assess the strength of health care facilities. She gave the example of a
woman and her HIV positive child living at a hostel in the Kibera village in Kenya. For fear of
discrimination, this mother hid her child’s medication and gave them haphazardly when no one
was watching. Since the therapy was not followed religiously, her child is now on second-line
treatment (G. McCullough, personal communication, October 30, 2014).
Another factor to this issue is that drug resistant strains develop quickly in children, and
progression of HIV occurs rapidly during the first few months of an infant’s life. In a South
African study conducted in 2008, up to 80% of infected infants well at 6 weeks of age had
progressed by 12 months of age to become eligible to start an ART (Volari et al., 2008). Another
study conducted in Mali on HIV positive children observed that nearly 25% of the cohort
developed resistance to HIV after 6 months on ART (Germanaud et al., 2010). Once again,
appropriate diagnostics at an early age are necessary in order to get children started on ART as
soon as possible. With the greater push to initiate ART earlier, there is the unknown of how the
virus and treatment will affect the child as he or she grows. Mrs. McCullough notes that adults
can have 50 years of life on ART, but this timeline is undetermined for children (G.
McCullough, personal communication, October 30, 2014).
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It is easy to say that better diagnostics are needed; however, this is difficult to accomplish
because infants require different tests than older children and adults. Those older than 18 months
can be given a serological test to determine HIV status. This type of test detects any antibodies
the patient’s body has developed against HIV. However, this test cannot be performed on infants
younger than 18 months since the test cannot determine the mother’s antibodies from the
infant’s. For this group, virological tests must be performed. This test detects the molecular
components of the HIV including its RNA (Antiretroviral Therapy for HIV Infection in Infants
and Children, 2010).
As previously mentioned, HIV prevalence varies among sexes, age groups, and location.
Currently in Sub-Saharan Africa, there is terrible adherence among teenagers. Mothers leave
their 12 year old children in charge of their own medication which leads to problems down the
line. After a few years on treatment, many of these children interrupt their therapies and go on
“holidays”. This term is taken from an HIV-positive girl interviewed by Mrs. McCullough in
Kenya. She explains that many adolescents start to feel better and wonder of a life without HIV
medication. This is obviously a major problem since ART is a lifetime treatment and must be
taken religiously for it to be most effective (G. McCullough, personal communication, October
30, 2014).
Opportunities for Pediatric HIV Care
At first glance, the challenges seem daunting; however, there are many opportunities for
success in regards to pediatric HIV treatment. Despite the treatment gap among children, South
Africa has the largest ART program covering nearly 1.79 million patients primarily through the
public health sector (Kiepiela et al., 2014). Since this country is classified as middle-income, it is
fairly self-sufficient in regards to meeting the health needs of its population. In addition, the
governmental response to the HIV epidemic has undergone a “complete transformation”. In
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2009, President Jacob Zuma broadened HIV drug access to pregnant women and infants and
encouraged an earlier initiation of ART. The increased capacity of South Africa to manage HIV
is seen in that most of the treatment is now funded by the government (L. Nelson, personal
communication, November 17, 2014).
Another advantage is that the fight against pediatric HIV is a consolidated effort among
the international community. Among the numerous actors are UNITAIDS, the United States
President’s Emergency Plan for AIDS Relief (PEPFAR), UNAIDS, the Global Fund, and CHAI.
In a combined effort, each can contribute differently in order to maximize the public health
impact.
That same cohort of caregivers who identified barriers to ART access and adherence also
provided supportive factors towards access. Participants offered that observing the improvement
of their child’s health after being on ART improved their confidence in administering the
regimen and the reasons for adherence. Additionally, attending treatment classes and talking to
other parents improved their understanding of ART (Ngobeni-Allen et al., 2013). Lisa Nelson
with the Global Fund agrees that peer support and working with communities is vital in
increasing adherence. Other suggested strategies for improved adherence include training of
health care workers, counselling services and family clinics where mother and child can receive
access simultaneously. By increasing support for these women, they are more freely able to
accept their status or the status of their child and move on to treatment.
In addition to improving PMTCT strategies, South Africa has also devoted significant
resources into other testing and treatment options. In 2004, the South African Comprehensive
HIV and AIDS Care, Management and Treatment Plan made highly active ART (HAART) more
available to the masses. Two years later, early diagnosis of HIV in infants was made possible
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with the introduction of DNA polymerase chain reaction (PCR) testing. Huge strides have been
made since then to increase access to the testing. Although PCR testing capacity was only at
27% in 2006, it dramatically increased to 70.4 % in 2011 (Meyers et al., 2007). With a large
ART program, the opinions of those immediately impacted by the HIV epidemic, and the
increase in diagnostic tools, South Africa is positioned to reduce transmission and improve the
quality of lives for those infected.
The National HIV Prevalence, Incidence, and Behavior Survey conducted by the South
African Human Sciences Research Council used HIV incidence testing to measure the number of
new cases (2014). This novel approach alone shows the increased national ability to monitor this
epidemic. Previous surveys only had the ability to measure prevalence, or the number of people
infected with the virus. The overall results point to a decline in HIV incidence since its peak in
2005; however, the decline is not as prominent as hoped.
In 2009, Dr. Reuben Granich and his team of researchers from UNAIDS suggested a
unique approach towards eliminating HIV infection among the South African population. There
modeling suggests that providing universal, voluntary HIV testing and immediate ARV therapy
for those who test positive along with existing preventative measures could “reduce the
prevalence of HIV to less than 1% within 50 years”; thus, changing the generalized status of the
epidemic (Granich et al., 2009). The driving force behind the success of treatment as prevention
is that if you can get viral suppression down in a population, than transmission should also be
reduced (R. Granich, personal communication, November 7, 2014). This study shows major
promise in the future of the HIV epidemic in South Africa, yet it hinges on having access to
testing and treatment for all, which is not yet available.
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WHO Pediatric ART Guidelines
In an effort to provide universal and comprehensive HIV treatment, the WHO produced
the “Consolidated Guidelines on the use of ARV Drugs for Treating and Preventing HIV
Infection” in June 2013 as an update of the 2010 guidelines. The influence behind these
guidelines is strengthened by the fact that many institutions contributed to their development
including the South African Medical Research Council. WHO takes a humanitarian approach
towards the HIV epidemic by recognizing access to HIV prevention, treatment, care and support
as a universal right to health (2013). It runs in full circle in that the denial of human health rights
increases the risk of HIV infection, and “HIV infection increases the risk of human rights
violations” (National Strategic Plan on HIV, 2012, p.30).
The complexity of pediatric HIV can be seen in the WHO recommended first-line and
second-line therapies provided in Table 1. The recommendations are dependent on age, and
second-line options are, as previously mentioned, dependent on what first-line therapy was
prescribed. Of most importance is the use of a LPV/r-based regimen as first-line ART for all
HIV-infected children younger than three years, regardless of exposure to ARVs during a
PMTCT strategy (Consolidated Guidelines, 2013). Several studies support the recommendations
to use LPV/r rather than an unboosted PI regimen. One such study conducted by van Zyl et al.
found resistance mutations in 12 of 17 patients on a single PI therapy compared with 1 of 13
patients on an LPV/r-based regimen (2009). Von Wyl et al’s study in 2013 further supports the
idea that “ritonavir boosted PI regimens allow for more potent viral suppression,” because they
exhibit a high genetic barrier to resistance (2013). The WHO recommendations are extremely
useful for national health departments when making policy; however, the challenges of pediatric
HIV care rule in that if certain drugs are not available, they cannot be employed in ARTs,
regardless of how optimal they are. In addition the recommendations of a PI-based regimen over
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an NNRTI-based
based regimen are supported by the findings of Pillay et al. Of the 73 patients on a
NNRTI regimen, 80% had both NNRTI and NRTI mutations while only 1 in 17 patients on a PI
regimen had resistance mutation ((2014).
Table 1. Summary of recommended fi
first-line and second-line
line ARV regimens for children
(including adolescents)

From the “Consolidated
Consolidated Guidelines on the use of ARV Drugs for Treating and Preventing HIV Infection June 2013”

In addition to advice on what to prescribe, these guidelines also give recommendations on
when to initiate ART in children. The major changes from the 2010 edition ar
aree that ART should
be initiated among infants
nfants and children five years of age or less, regardless of WHO clinical
c
stage or CD4 cell count, those
hose older than 5 years of age with a CD4 count ≤500
500 cells/mm3, and
among all HIV-infected
infected children in WHO clinical stages 3 or 4 regardless of CD4 count
(Consolidated Guidelines, 2013))
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Each of these recommendations has certain important implications. First, for those
younger than 5, disregarding clinical stage and CD4 count widely opens access to treatment.
Perhaps the most significant change is that in treatment eligibility from a CD4 of ≤350 cells/mm3
to ≤500 cells/mm3 for those older than 5 years of age. It is much more inclusive; however, not
many countries have the capacity to manage this switch yet as viral load testing is not readily
available (G. McCullough, personal communication, October 30, 2014). Weak health care
capacity is also a reason for the third recommendation. In regions where viral load or CD4
testing is not readily available, clinical staging is the only diagnostic tool to use.
South African National Guidelines
Even though the WHO guidelines are comprehensive, they are certainly not implemented
evenly across all countries. Additionally, it is a lengthy process to develop and implement policy
at the national level, and even more time passes before written policies are accurately reflected in
program implementation and clinical practice (R. Granich, personal communication, November
7, 2014). Managing these changes, such as the new ART eligibility CD4 count, is difficult for
many low and middle-countries. Specifically with this change, the influx of eligible patients puts
a strain on the health care system. However, South Africa has been diligent in keeping up with
the changes made and its policies are almost in full compliance.
For children under three years of age, the recommended first-line therapy is ABC, 3TC,
and LPV/r. For those older than three years of age, it is ABC, 3TC, and EFV. Second-line
therapies are also in accordance with the WHO in that the recommended regimen is AZT, 3TC,
and LPV/r. The complete suggested regimens for infants and children are outlined in Table 2
(Department of Health Republic of South Africa, 2013). The Department of Health is also
following the phase out of d4T by recommending a switch to ABC if viral loads are
undetectable.
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Table 2. Summary of South African nationally recommended first-line and second
econd-line ART
regimens for infants and children

Taken from the South African National Antiretroviral Treatment Guidelines 2013

In addition to the standardized regimen
regimens are the national monitoring procedures for
infants and children living with HIV. Routine measurements of weight, height, development,
CD4 count, WHO clinical staging, and TB status are performed at initial diagnosis of HIV and at
follow up appointments (Department
Department of Health Republic of South Africa, 2013).
). These protocols
are necessary in order to monitor the development of HIV; however, a major problem is getting
patients to come to the clinics
ics for follow
follow-up
up appointments. The long distances from home to
clinic and the long lines deterr many mothers from bringing their children in for appointments.
Despite this, by being in accordance with the WHO guidelines, these national policies will
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expand the number of children able to get treatment and will provide support for proper
adherence to their therapies (R. Granich, personal communication, November 7, 2014).
South Africa does lag behind the WHO in several areas as portrayed in Table 3. For ART
initiation eligibility for asymptomatic people, South Africa plans to move eligibility to a CD4
count of ≤500 cells/mm3; however, it has yet to be implemented in the national strategy (The
Global Database, 2014). This exposes the disparities between the Northern and Southern
approach to HIV treatment. In the United States and other Western countries, treatment is given
at a higher CD4 count, yet in areas where HIV is most prevalent, treatment is not initiated until a
lower CD4 count. Similar disparities exist for pregnant women in that Option B+ is the standard
for Northern countries while in South Africa, a CD4 count of ≤350 cells/mm3 is required for
ART initiation. Finally, by decentralizing ARV distribution to the community level, more people
have access to treatments. This is especially necessary for South Africa since the clinics cannot
manage the full demand for ART.
Table 3. A Comparison between WHO and South African National ART Treatment Guidelines
Policy
WHO Guidelines
South African Guidelines
(Consolidated Guidelines, 2013)

ART Initiation Eligibility for
Asymptomatic People
ART Initiation for pregnant
women
Frequency of CD4
Monitoring
Frequency of Viral Load
Monitoring
Nurse Initiation of ART?
ARV Dispensing at
Community Level?
When to Initiate ART for
Infants?

(Department of Health Republic of
South Africa, 2013)

CD4 count ≤500 cells/mm3

CD4 count ≤ 350 cells/mm3

Irrespective of CD4 count
(Option B+)
Every 6 months

CD4 count ≤ 350 cells/mm3
12 months of age

Month 6, 12, 24 and yearly
after month 24
Yes
Yes

Month 6, 12, 24 and yearly
after month 24
Yes
No

Immediately regardless of
ARV exposure

Exposure to ART: NVP at
birth then daily for 6 weeks
No exposure to ART: NVP as
soon as possible then daily for
6 weeks
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NGO Strategies
The multilateral fight against HIV/AIDS includes many actors in the international
community including WHO, UNAIDS, UNITAIDS, the United Nations Development Program
(UNDP), the Global Fund, CHAI, and PEPFAR. This list is not exhaustive as there are countless
others working in collaboration. The intertwining relationships among these organizations are
delicate in that desires and interests have to match in order for there to be effective treatment
development and distribution, along with policy development.
Although WHO has developed the bulk of international recommendations for HIV ART,
UNAIDS provides global leadership in the response against this epidemic. This organization gets
some funding from PEPFAR, and there is collaboration with UNITAIDS on providing funds for
testing and with CHAI on monitoring the epidemic (R. Granich, personal communication,
November 7, 2014). The Global Fund a new funding model as of last year where the ability of a
country to pay for health services and their need are dually considered when grants are given. So
that countries no longer compete for grants, money is set aside for each country until it can
submit a good application for a grant. There are nine active Global Fund grants in South Africa
targeted towards HIV/AIDS, all managed by the country coordinating mechanism. This focal
point proposes what to do with the money, decides when to apply the grants, and decides who
the principle recipients of care are (L. Nelson, personal communication, November 17, 2014).
Many of the projects of UNITAIDS are focused on HIV treatment, and although only one
is directly active in South Africa, a lot of the work benefits this country. One of the largest
UNITAIDS projects titled “Pediatric HIV/AIDS Project” ran from 2006-2014. With a budget of
$418,474,634 USD and CHAI as the lead implementers, this effort has vastly improved the
pediatric ARV market. By increasing the confidence in pharmaceutical companies to invest in
pediatric ARVs, antiretroviral prices have decreased, and there are more generic medications and
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adapted FDCs. The dramatic decrease in pediatric HIV treatments can be seen in Figure 1. In
2006, a leading ARV cost $252 USD while in 2011, this price dropped to $130 USD per patient
per year (ppy) “due to high-volume
volume drug purchas
purchases” (Paediatric
Paediatric HIV/AIDS Project,
Project n.d.).
Another major strategy
trategy for market intervention includes providing point-of-care
care and
decentralized diagnostics. This is a significant aspect of the “Better
Better HIV Treatment for Infants
and Young Children Program” implemented by the Drugs for Neglected Diseases Initiative.
Point-of-care
care treatment, such as portable machines to measure CD4 count, involves moving
treatment closer to the site of patient care so that results are received conveniently and quickly
(Better HIV Treatment for Infants
Infants, n.d.). Finally, increasing
ncreasing access to new HIV monitoring
technology such as viral load testing and early infant diagnosis will allow medical workers to
follow the development of the virus and the effectiveness of drug formulation
formulations.

Figure 1. Mediann price (US$ ppy
ppy) of pediatric first-line
line treatment regimens, 2004-2013
2004
Taken from the Access to Antiretroviral Drugs in Low
Low- and Middle-Income
Income Countries July 2014 Technical Report
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Improving the market for second-line treatments is also a key area of work for
UNITAIDS. For adult regimens, prices have fallen 73%: In 2006, the leading second-line
regimen of TDF, 3TC, and LPV/r cost $1,500 USD ppy. Today, the price is now $527 USD ppy
(Better HIV Treatment for Infants, n.d.). These advancements are promising in the effort to
provide access to every patient in need; yet, it will be interesting to see whether pediatric secondline regimen prices will follow suite in similar reductions. Before this can be accomplished, there
needs to be a more competitive market for second-line therapies for children. Finally, WHO has
identified several key formulations not available for children including ritonavir-boosted
darunavir (DRV/r), a combination that could be used for children failing a first-line regimen
based on LPV/r (Paediatric HIV Treatment Initiative, n.d.).
WHO and South African Response to HIVDR
In regards to HIVDR, the WHO recommends country-wide surveillance and monitoring
systems for the pediatric HIV population (Antiretroviral Therapy for HIV Infection in Infants
and Children, 2010). South Africa, being more self-sufficient in the HIV fight, has a stronger
capacity than most Sub-Saharan African countries to manage these systems. New reports
released by the WHO include strategies to support the sustainability of HIVDR surveillance
programs. This global strategy encompasses assessment tools for TDR surveys, ADR surveys,
and Surveys of HIVDR in infants younger than 18 months of age, all of which require HIVDR
genotyping. The goal of each survey is to inform selection of optimal therapies for the target
populations (Meeting Report: Implementation & Sustainability, 2014).
For TDR, it is recommended that countries incorporate surveillance into existing routine
diagnostic testing activities. The ADR surveys will assess levels of viral suppression at two key
time intervals: 12-24 months and 48–60 months after treatment initiation. The final survey
involving pediatric populations aims to inform selection of optimal first-line ART. Success of
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this survey is linked to the strength of early infant diagnostics in that if infants are quickly
diagnosed, they can have immediate access to optimal therapies (Meeting Report:
Implementation & Sustainability, 2014). A question to pose is whether there are any surveillance
systems in place to measure HIVDR among children failing first-line ART? If not, is it feasible
to initiate such programs into South Africa’s health care system?
Included in this report are the draft HIVDR surveillance priorities and plans established
by South Africa for 2013-2017. A working group of a clinical team, laboratory group, and
epidemiology development group will manage these monitoring surveys. Funding will be
temporarily managed by the CDC and Global Fund until they can be “integrated in [the] national
health budget”. These surveys and genotype testing are a great tool in the mapping of resistance
patterns; however, there are several limitations to this approach in South Africa. For example,
data in this country is available through over 4,000 clinics, yet many of these clinics operate in
paper-based reporting. There is a need to centralize all reporting so that samples are unbiased and
reporting is accurate. Additionally, TDR surveys are currently provincial (Meeting Report:
Implementation & Sustainability, 2014). Many question whether a nationally representative
estimate of TDR can be obtained from this method. The solution might be regional surveillance,
yet the costs are too large to justify this approach.
Drug Resistance Testing
The idea behind drug resistance testing is that sequencing a virus’s genome can be used
to optimize the use of ART in individuals experiencing virological failure. This test detects
changes in the viral genome, in the form of mutations, which make the individual less receptive
to the medication (Imperial College London, 2013). It can also be used to determine whether the
underlining issue is drug-resistant mutations or lack of adherence. Although this is an extremely
useful tool when tailoring treatments, each of the participatory experts in this study commented
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that it is not a cost-efficient option for South Africa at the current moment. A genotypic test
today costs about $300. Referring back to Figure 1, one can see that the median price of the
recommended pediatric first-line therapy of ABC, 3TC, and LPV/r is slightly more than $250
ppy. Since one test costs more than a year’s worth of treatment, it is unlikely that genotypic
testing will be implemented nation-wide in the near future. However, if the cost of such tests
decreased, there would be more incentive to increase their use. Dr. Nelson identified the need for
a low cost strategy with drug resistance testing and provided the example of the rapid GeneXpert
test which has had huge success in detecting tuberculosis and Rifampicin resistance (Personal
communication, November 17, 2014). Due to the huge issue of mal-adherence, sequencing the
genome of the HIV virus would keep patients with perceived virological failure but no resistant
mutations from switching to a more costly second-line therapy.
Lessells et al weigh the opportunities and difficulties of implementing widespread HIV
genotypic testing. They argue that as more formulations become available for use, the demand
for individualized resistance testing will increase to aid clinics in the “management of virological
failure.” The benefits of drug resistance testing include the conservation of first-line therapies
and targeted interventions to resolve adherence issues. They also posit that since third-line
therapies are so expensive, it is worthwhile to invest in a genotype test so that the patient has a
smaller risk of virological failure (2013).
Over the last decade, laboratory capacity in South Africa has grown tremendously where
17 laboratories now perform nearly two million viral load tests per year. Advancements in the
area of resistance testing have been made by The Southern African Treatment and Resistance
Network to reduce the cost of sequencing and number of sequencing primers. An expansion of
training and teaching for health workers will be required to accommodate for the rise in technical
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ability needed (Lessells et al., 2013). Despite the success, it is important to remember that
statistics do not always portray the reality of the situation. For instance, it is not only about how
many tests are performed, but who is actually being tested (D. Tarleton, personal
communication, November 13, 2014. Are the targeted populations, such as young women, being
reached by these services?
In one of the largest studies of adult HIV drug resistance in South Africa, 86% of the 222
enrolled participants with evidence of virological failure from a first-line ART regimen had at
least one drug resistance mutation. Each participant was given a genotype test to determine the
presence of drug resistant mutations. This study conducted fairly recently between December
2010 and March 2012 also reported that one in seven had complex resistance patterns “with the
potential to limit the efficacy of the standard second-line ART regimen” (Manasa et al., 2013,
p.4). Although some might argue that these resistance tests are unnecessary since the majority of
participants had confirmed drug resistance, yet this study reveals that one in seven could have
difficulties responding to standard second-line care. Knowing this ahead of time allows medical
workers to prescribe a therapy, if the drugs are available, which have the greatest chance of
achieving viral suppression (Manasa et al., 2013). The results from this study are widely
applicable to South African adults, but can the same be said for infants and children and are there
other benefits or complications with genetic testing among a younger population?
Recommendations for South Africa Department of Health
In order to improve performance of ART, testing must be coupled with counseling. With
the target for 2016 of 30 million men and women tested and counseled for HIV, South Africa is
well on its way to achieving access to both services. Another component of this national strategic
plan to end HIV is the bottom-up approach to governance. Reporting and monitoring of HIV will
“start at ward level through districts”, go to the provincial level through Provincial AIDS
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Councils, and end at the national level through the South African National Aids Council. The
hope is that a clear framework for policy implementation will guide this entire process (National
Strategic Plan on HIV, 2012).
One way to address the human rights issue of HIV/AIDS is to tackle the stigma and
discrimination associated with a diagnosis. Efforts must be made at the national level for changes
to be seen at the provincial and district level. Yet, it is difficult to make laws targeting human
behavior. It cannot simply be a regulation against discrimination. There must be proper
enforcement which will require a scale-up of existing systems. One suggestion is to use media to
raise awareness of this problem. However there are complications with this approach, because
individuals might disregard the message, viewing them as inapplicable to their lives. Another
suggestion is to increase HIV education and peer support so that the population is more
knowledgeable of the epidemic and how discrimination can lead to poor adherence and drug
resistance.
Reducing stigma and discrimination is also linked to the idea of prevention as treatment.
With the subject of drug resistance, this concept is more upstream. If a mother never got
infected, she would never transmit to her kids, and that child would never deal with the problem
of HIV drug resistance. Of the billions of dollars spent on HIV in 2012 in South Africa, only
10% was for prevention (Human Sciences Research Council, 2014). South Africa must invest
more heavily in preventative measures so that these efforts match those being taken with
treatment. Of course, an overall increase in spending on HIV would help the fight against this
epidemic, but the issue of funding is always at the forefront.
A significant problem with HIV among the pediatric population in South Africa is that
health workers are not finding the children in need (G. McCullough, personal communication,
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October 30, 2014). Once the children are found, diagnostic tests can be performed, results given,
and treatments prescribed. Of course, each of these areas requires improvement such as faster
test results at the site of care and more manageable ARV formulations. Access to testing and
treatment would dramatically increase if more medical workers were trained to deliver diagnostic
and clinical services. This will require the South African government and Department of Health
to increase the amount and quality of training being offered to workers.
An overall simplification of the system might prove beneficial for South Africa. For
instance, providing assistance to mothers will help them get their children to the clinics. In
addition, clinics where both mothers and children can receive ART simultaneously will
incentivize mothers to visit. With the improvement of the pediatric first-line ART market, there
is strong hope of similar improvements with second-line and third-line regimens. Third-line
regimens are still very much in the clinical stage. They are extremely expensive, costing around
$3,500 USD ppy and there are very few options. Their limited availability is problematic for all
involved. Mrs. McCullough gave an example of parents splitting pills manufactured for adults in
half for their children’s ART (G. McCullough, personal communication, October 30, 2014). This
is blind dosing, because the active ingredients in the pills are not distributed evenly throughout.
Even if a child has access to third-line therapies, the challenges of the regimen are enormous.
Some of the infected children Mrs. McCullough has visited in Kenya are taking nine pills in the
morning and in the night (G. McCullough, personal communication, October 30, 2014).
Simplifying this regimen with fewer pills would lead to better adherence.
Another issue to confront is the lack of studies among pediatric populations. There are
many contributing factors behind this including participant accessibility, funding, and ethics. It is
difficult to get permission and consent from not only children but their parents in order for them

Hendrix 33

to be a part of these trials. There is also the question of whether the money funding these studies
would be more useful to provide testing and treatment for the millions in need. This plays into
the ethical considerations of genotypic testing. Is it ethical to research this new form of testing in
Sub-Saharan Africa, a region that needs the technology the most but has the least accessibility?
Finally, you must look what ART regimens clinics have. If the stock only includes one first-line
and one second-line option, genotypic testing provides no help (R. Granich, personal
communication, November 7, 2014).
An alarming recommendation from the WHO 2013 Guidelines is that children on failing
second-line regimen with no new drug options should “continue with a tolerated regimen”
(Consolidated Guidelines, 2013, p.33). The initial step must be the production of third-line
therapies. Once this is accomplished, laboratory capacity can be increased and children requiring
this level of medication will have higher chances of survival. Yet, there is a debate over whether
testing or treatment is more efficient in curving the HIV epidemic. Some argue that resistance
testing is not a solution to the problem of drug resistance and advocate for reductions in the
emergence and spread of the virus as a means of improving HIV ART programs.
Due to the economic implications, the author does not advise the use of genotypic testing
in routine clinical care in South Africa. Several other limitations exist with genotypic testing
making it less practical for today including the current fragility of the drug supply chain and the
difficulties with “operationalizing” this service into routine care (L. Nelson, personal
communication, November 17, 2014). However, the question lingers as to what can be learned
from studies involving this type of diagnostics. For instance, what could we learn from a study of
3,000 children given genotypic testing (G. McCullough, personal communication, October 30,
2014)? The funding could come from UNITAIDS and the cohort of children could come from
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the Nyumbani Children's Home in Kenya operated by Sister Mary Owens. This children’s home
already serves thousands of HIV infected children; thus, it would solve the issue of accessing
children for studies previously mentioned.

Conclusion
HIV drug resistance among infants and children in South Africa is a multi-faceted issue.
The WHO Guidelines revised in 2013 provide many recommendations in regards to HIV
antiretroviral testing and treatment for this population. The South African national treatment
guidelines are, for the most part, in accordance with the WHO. However with more children
eligible for ART, there will naturally be more drug resistance. Many nongovernmental
organizations are working in collaboration on the fight against pediatric HIV including
UNITAID, UNAIDS, and the Global Fund.
There are many areas of improvement to be made in order to reduce drug resistance. At
the forefront is the problem with adherence. Antiretroviral therapies must be taken religiously in
order for them to be effective. Also, the longer drug resistance goes undetected, the more
amplified the resistance becomes. This problem can be addressed by simplifying the pediatric
ARV market and the overall access to medications. Providing formulations in solid form, which
taste better, and are heat stable will increase adherence. In addition, peer support and community
outreach will encourage mothers to get their children tested and to disclose their status. South
Africa is a unique case in that it is middle-income country and has greater laboratory services
than neighboring countries. Drug resistance testing is a beneficial tool in that it identifies
resistance patterns so that specified regimens can be prescribed for individuals. Yet, in South
Africa, resources must first go to providing universal testing and treatment; therefore, this
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service is not advisable in routine clinical care. Perhaps the answer lies in providing treatment as
prevention, an area of future research with this subject.
Other opportunities for future research with this subject. Once the cost of genotypic
testing decreases and when the funding is available, a large study of pediatric HIV drug
resistance where the patients are sequenced would be extremely beneficial in the efforts to
eliminate HIV. When viral loads are high, transmission and the burden of HIV increases. With
drug resistance testing, patients can be put on specialized treatments to solve the problem of mal
drug absorption, or their difficulties with adherence can be addressed and managed. The current
situation in South Africa does not yet allow from wide-scale genotypic testing, yet, the benefits
are definitely worth the efforts to make this diagnostic tool more accessible. Additional future
research could include studies on how ART initiated early in life impacts that child physically
and mentally as he grows to maturity. Limitations of this study include the lack of new raw data
on pediatric HIV in South Africa.
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Acronym and Abbreviation List
3TC

Lamivudine

ABC

Abacavir

ADR

Acquired Drug Resistance

ART

Antiretroviral Therapy

ARV

Antiretroviral

AZT

Zidovudine

CHAI

Clinton Health Access Initiative

d4T

Stavudine

DRV/r

Ritonavir-Boosted Darunavir

EFV

Efavirenz

FDC

Fixed-Dosed Combinations

HAART

Highly Active ART

HIVDR

HIV Drug Resistance

LPV/r

Ritonavir-Boosted Lopinavir

NNRTI

Non- Nucleoside Reverse Transcriptase Inhibitors

NRTI

Nucleoside Reverse Transcriptase Inhibitors

NVP

Nevirapine

PDR

Pre-treatment Drug Resistance

PEPFAR

President’s Emergency Plan for AIDS Relief

PI

Protease Inhibitors

ppy

Per Patient Per Year

TAM

Thymidine Analogue Mutations

TDF

Tenofovir

TDR

Transmitted Drug Resistance
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UNAIDS

Joint United Nations Program on HIV/AIDS

UNDP

United Nations Development Program

WHO

World Health Organization
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Work Journal
10/9/14

Duration: 0:15

Today I had my first ISP Advising Session at Ecole Club Migros in Nyon, Switzerland. The
meeting was with Dr. Alexandre Lambert. We discussed the preliminary idea for my ISP which
was high HIV prevalence among women in South Africa. I was directed towards several NGOs
such as UNAIDS for sources of interviews.
10/10/14

Duration: 0:15

I had my second ISP Advising Session at the SIT Office in Nyon, Switzerland with Dr. Heikki
Mattila. We talked about the final proposal which I had submitted earlier. My topic was still why
there is a higher HIV infection rate among women than men in South Africa. I was told that my
project passed the ethics review board and that I could begin my research.
20/10/14

Duration: 4:30

I started my research today by searching the internet for credible secondary sources in the area of
gender and HIV infection in South Africa. This research was complete at my homestay in
Bursins, Switzerland.
21/10/14

Duration: 5:00

After reviewing the presentation given to our program at the WHO about UNITAIDS by Mrs.
Gelise McCullough, I became interested in pediatric HIV. I was so inspired that I changed the
topic of my ISP to HIV drug resistance among infants and children in South Africa. I was
curious as to some of the determining factors of HIV drug resistance and how this problem is
being addressed among pediatric populations. I then researched secondary sources for
publications and studies on this topic through journal databases such as PLoS ONE (the Public
Library of Science), PubMed.gov, and Web of Science. This was carried out at the UNOG
Library, Palais des Nations 1211 Geneva.
22/10/14-27/10/14

Duration: 32:00
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During this week, I did a lot of research on my topic at various locations including my homestay
in Bursins, the UNOG Library at the Palais des Nations, the SIT office in Nyon, and the
Starbucks by the Geneva train station. It was a little overwhelming at times, because I was
finding a lot of information on HIV infection among children and drug resistance. There was a
lot to sort through and some of the dialogue was challenging due to its scientific nature.
Throughout this period, I contacted several potential interviewees. On 23/10 I emailed Dr.
Martina Penazzato and Mr. Martin Auton from the ARV Procurement Working Group and the
World Health Organization. Then on 25/10 I emailed more potential interviewees including Dr.
Marc Lallement and Dr. Brian Eley, members of Technical Reference Group on Pediatric HIV
Care and Treatment: South Africa. I emailed Mrs. Dorine Da re-van der Wal from the WHO to
refer me to Gelise McCullough since I did not have her email from the presentation. Finally, I
emailed Dudley Tarlton, who gave our program a presentation on the UNDP’s partnership with
the Global Fund and their efforts to end HIV/AIDS.
28/10/14

Duration: 5:30

Today, I secured my first formal interview with Gelise McCullough, Technical Director for
UNITAIDS. We scheduled the interview for Thursday October 30, 2014 at 10:00 at the WHO
building in Geneva. I was considering asking her to be my advisor after the interview. I
continued writing my paper too.
29/10/14

Duration: 6:30

While at the Starbucks in Geneva, I continued my research. I also started writing my paper
today. I completed the first draft of my introduction.
30/10/14

Duration: 2:00

Today, I had my formal interview with Gelise McCullough at the World Health Organization.
Avenue Appia 20 1211 Geneva 27 Switzerland. We sat in the café, drank coffee, and talked
about pediatric HIV and the work of UNITAIDS in the WHO cafe. All of my prepared questions
were answered and then we spent twenty minutes just discussing more about pediatric HIV in
general such as TB co-infection and PMTCT efforts. Hand notes were taken throughout the
interview. I learned about her side work where she paints her experiences and uses the profits to
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fund children’s education. At the end of the interview, Mrs. McCullough agreed to be my advisor
and gave me several contacts for more interviews. The two contacts were Dr. Badara Samb with
UNAIDS and Francesca Celletti with EGPAF. Afterwards, I reflected on the interview and typed
up my transcript. She also told me that the money she would get from being my advisor would
be sent to a child in Kenya to fund his/her education which is really exciting!
05/11/14

Duration: 7:00

I continued writing my paper and completed the first draft of chapters titled: Pediatric HIV in
South Africa, Pediatric HIV Drug Resistance, Challenges to Pediatric HIV Care, and
Opportunities for Pediatric HIV Care. This writing occurred in SIT office in Nyon, Switzerland
and at the Starbucks in Geneva. I was having trouble finding other interviews since none of the
experts I emailed responded.
06/11/14

Duration: 6:00

While writing my paper, I received a response from Dr. Samb saying that he was traveling for
the remainder of the year but he referred me to Dr. Reuben Granich, a Senior Advisor of Care
and Treatment for UNAIDS. I sent an email to Dr. Granich explaining my research and
requesting an interview. He responded within several minutes and I set up my second formal
interview for the following day at 10:00 at the UNAIDS building. I then continued drafting my
paper with the chapter on the WHO Pediatric ART Guidelines and prepared the questions for my
interview the next day.
07/11/14

Duration: 3:00

My second formal interview was today with Dr. Granich at the UNAIDS building Avenue Appia
20 1211 Geneva 27 Switzerland. Luckily it was across the street from the WHO main building,
so I had no trouble finding this location. Questions were prepared but conversation deviated from
those topics slightly. I found two WHO technical reports, “Access to Antiretroviral Drugs in
Low-and-Middle-Income Countries July 2014” and “Technical and Operational Considerations
for Implementing HIV Viral Load Testing July 2014” that I was allowed to take with me for
further research. Additionally, I asked if there were any conferences or public events. Dr.
Granich said he would invite me to any meetings if there were any in the near future. I returned
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to my homestay to type the transcript. Here, after asking about my interview, my host mom told
me that our old neighbor, Paula Hacopian (who moved a week after I arrived in Switzerland)
worked with the subject of HIV/AIDS. She said she would call and ask if she was available to
meet with me.
08/11/14-09/11/14

Duration: 14:00

These days were spent writing my paper at the SIT office in Nyon. I worked on the chapters of
the South African National Guidelines, NGO Strategies, and the WHO and South African
Response to HIVDR. I could not find the phone numbers for the experts who did not respond, so
I sent a second email asking if my first had reached their inbox.
10/11/14

Duration: 6:00

My host mom gave me Paula’s number and said that I could call to schedule a meeting. After
several tries, I left a message. Paula called me back while I was working on my paper in the SIT
office. She said that she worked with the Global Fund and would contact a colleague who was
more knowledgeable in the field of pediatric HIV.
11/11/14

Duration: 6:30

I got a response today from Dudley Tarlton, and we set up a formal interview for the upcoming
Thursday at 11:00 at the UNDP. I also got an email from Dr. Lisa Nelson, the colleague of Paula
Hacopian. Even though she was working in South Africa, she said she would be back in
Switzerland the following week. We scheduled the meeting for the upcoming Monday,
November 17, 2014. The rest of my time was spent preparing the questions for my interview on
Thursday and writing the paper.
13/11/14

Duration: 2:00

My third formal interview was today at 11:00 at the UNDP located at 11-13 Chemin des
Anémones, 1219 Châtelaine, Geneva with Dudley Tarlton. His colleague, Fabien Lefrancois also
joined for the interview. I learned that the UNDP does not deal directly with the Global Fund
grants in South Africa but both interviewees provided a lot of helpful information on
procurement of grants and how the UNDP works to develop capacity.
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16/11/14

Duration: 4:00

On my train ride back from Milan, I typed up my notes from my interview on Thursday and
added some of that information to my paper. Once I returned home, I edited my paper and
prepared the questions for my interview on Monday.
17/11/14

Duration: 5:00

I had my final formal interview today with Dr. Lisa Nelson, a Senior HIV Disease Advisor with
the Global Fund. Our interview lasted for 45 minutes and was held in the café of the Global Fund
building located at Chemin de Blandonnet 8 1214 Vernier-Geneva, Switzerland. She had just
been travelling in South Africa and I learned a lot about the global fund grants in this area. After
the interview, I returned to my homestay and typed up the transcript. I then finished the first draft
of my paper which I emailed to my advisor to edit.
18/11/14

Duration: 7:00

In the morning at my homestay, I edited my paper again and completed the interactive research
log. I also started my presentation which I will give on Thursday. I decided to use Powerpoint
during the presentation. I then went the SIT office in Nyon where I continued my work.
19/11/14

Duration: 6:30

After the first day of presentations, I finalized my presentation. My advisor sent her edits back to
me today so I was able to make a final revision of my paper. I submitted the final copy to the
program director and academic advisor along with my powerpoint presentation.

Interview Transcripts
Interview 1
Interviewee: Gelise McCullough (GM): Technical Director UNITAIDS
Location: World Health Organization Avenue Appia 20 1211 Geneva 27 Switzerland
Date & Time: 30/10/14 at 10:00-11:00
Q: What is your job?
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GM: I have worked with UNITAIDS for 6 years. I work on strategy and am a civil society focal
point. So I work with those infected a lot. I do a lot of in-country consultations where I meet with
those infected, care-givers, and the government to make sure they are working together to
strengthen the health care system. I mainly go to medical facilities like hospitals where you can
really see the strength of health systems and what is lacking. I have been to many places
including Senegal, Liberia, Mali, Kenya, Tanzania, and Myanmar.
Q: Why do children have difficulty adhering to their ARV therapies?
GM: ARV has to be easy and children’s ARVs are not. There are weight bands to consider and
medicines are hard to take. There are also big difficulties in the market. Currently, LPV/r for
infants is only in syrup form which is bad-tasting. So there are three big reasons why children
have trouble adhering: 1) it is difficult to take 2) There are social factors involved. Women will
know their positive status but their husbands don’t so revealing the child’s status causes huge
problems. As an example, a Kabira woman living in a hostel hid her child’s medication and
didn’t give them religiously. Her child is now on 2nd line treatment. 3) A lack of good
diagnostics. When patients are monitored better by health officials, they do better on their
treatments.
Q: How close is UNITAIDS in bridging the treatment gap among children?
GM: The good thing about pediatric HIV is that we are not alone. There are many actors
working together including PEPFAR, UNAIDS with the political lobby, UNITAD, and the
Global Fund. We (UNITAIDS) have the diagnostics but PEPFAR will scale it up because they
have a lot more funding. Our public health impact is a combined effort. The treatments are there
but we’re not finding the children in need. We have been investing in early infant diagnosis
which is needed because diagnostic tests are different for children than for adults. (You can’t test
infants like adults because the mother’s HIV virus could be detected instead of the child’s). Now
there is a push to testing kids as soon as possible, at around 12 weeks. The problem is getting
mothers back in for results. Currently only 50% of mothers come back for results. So we need to
find the kids, get them diagnosed, get the results, get the kids on treatment, and have better
formulations.
Q: How does UNITAID work with other organizations?
GM: The interests and desires of UNITAID, PEPFAR, CHAI and others have to match which is
difficult at times. UNITAIDS doesn’t work directly with pharmaceutical companies, because we
have to keep neutrality in mind so there is no conflict of interests. But we (UNITAIDS) give
money to CHAI who gives money to pharmaceuticals.
Q: Do you think drug resistance testing (genotypic testing) before switching treatments is costeffective? (For instance, to determine if viral load is actually high enough to fail 1st line?)
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GM: Not at the moment. It is not viable right now because it costs $300 per test. Sister Mary
believes that now, when viral load increases (detected in a test) and there’s a switch to second
line treatment, this is a blind approach. It is like switching form one blind therapy to another.
You don’t know what resistant mutations there are or if the real problem is with resistance or
adherence. Another huge issue is that kids suffer very quickly from drug resistance. Maybe we
(UNITAIDS) could work with Sister Mary and her cohort of children. What could we learn if we
paid for 3,000 or so children to get genotype therapy?
Viral load testing is a blood test: how much virus is in the blood? If the virus is undetectable, the
medication is working. When the virus is detected, the therapy is either failing or the patient is
not taking his/her medications. You can count the number of drugs (pills) too but you can flush
them down the toilet. We are now doing a urine test to see if patients are taking their drugs
because people lie.
Q: Are there any viable third-line therapies for children?
GM: Not exactly. It’s still very much in the clinical stage. Sister Mary in Kenya gets them from
compassionate donations (she goes around and asks for treatments). They are so expensive
costing around $3,500 per year. People try using adult medication by splitting tablets but the pills
are not made evenly. So giving a child half of a pill doesn’t mean that you are giving them half
the dose. These treatments are not adapted well to children. One child on third line must take 9
pills in the morning and 9 at night. In Sister Mary’s cohort, kids have a lot of inherited
resistance. Those she treated early on in her program were just given whatever was available and
we are now seeing a lot of drug resistance.
Q: How can we reduce drug resistance among children?
GM: - Get testing done quickly and correctly at the start
- Help the mother get to care facilities so she can give the ART to her kids
- Simplifying medications makes it easier to treat kids. How easy would it be to only need to
give one pill in the morning?
In the Kenyan orphanage, children would discriminate each other based on how many pills the
other would have to take. All the kids have HIV and all are on ART but they are on different
programs. One might discriminate another saying “oh he has 4 pills, he’s sicker than me”.
Q: I was reading that UNITAIDS is only active with one program in South Africa, the
“Implementation of CD4 and viral load testing in decentralized, remote and resource-limited
settings in MSF HIV programs”. Are there any other programs in South Africa?
GM: South Africa is pretty self-sufficient. None of our projects directly go to South Africa but a
lot of our work benefit that country.
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---------------------------------------End of prepared questions---------------------------------------------Q: What about the WHO Guidelines for Treatment?
GM: They are very important. The biggest change was the CD4 count from 500 to 350. Not
many countries can manage this switch yet (viral load testing is not readily available). Countries
want to switch but don’t have the capacity to treat all of those patients. A simplification with
Point of Care diagnostics will help. It’s not often doctors that are doing the diagnostic work so
there needs to be more training.
Q: And the WHO recommendations…?
GM: Breast feeding exclusively. Moms get conflicted because they know they could transmit to
their kids if they breastfeed so they switch sometimes to bottle which is worse because it
damages the gastro-intestinal tract. Kids are tested at 12 and 18 months to see if viral load is
different and see if feeding has given the child HIV.
Q: How efficient is PMTCT?
GM: Birth is always a dangerous affair. There’s always a chance of transmission with blood
contact between the infant and mom. It often depends on the circumstance whether the kid will
be infected. It all depends on how quickly you diagnose the pregnant mom, whether she
continues treatment after birth, and how quickly you test the infant after birth. Pregnancy takes a
huge toll on the body: energy levels are down and the mother’s immunity goes down. When they
get sick, they have a higher viral load which means a higher chance of transmitting the HIVV to
the child.
The sad reality is that a lot of kids die in Africa. With a mother who loses a child, maybe it is her
HIV positive child that dies and she thinks “I’ll have another and maybe it will be okay”. There
is a lot of stigma and discrimination around HIV treatment and diagnosis. For example, it is
better if the child is severely malnourished than malnourished. The severely malnourished child
will stay in a hospital and get good care while the malnourished child gets extra food and
nutrients which the mom gives to all of the children in the family and not just the HIV positive
one. The stigma factor is a huge reason why mothers don’t get their kids tested.
Q: How does treatment as prevention work?
GM: In discordant relationships, one partner has HIV and the other doesn’t. The idea is that if
you can get viral suppression down in a group of people, transmission should be reduced. But in
Africa, men have multiple partners at a time and have multiple wives. Some wives think they are
lucky to have husbands and can’t control the sexual actions of their husbands (like ask him to
wear a condom etc). So he can go and have sex with others and bring HIV back to his wife. In
some relationships, when 1 wife is HIV +, the others want it because that means they are having
sex with their husband. Also other STIs are conductors of HIV.
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Q: Are there complications with ART?
GM: Another reason why children develop resistance to HIV drugs is due to toxicity and loss to
follow up. Adults can have 50 years on HIV treatment but with children, we don’t know how
long. When you grow up with HIV and on ART, how much effect does the virus have on the
child as he grows? Sister Mary notices that there are heart problems with her adult patients that
started treatment as kids.
There is terrible adherence with teenagers and specifically boys born with HIV. At 12 years old,
mothers disclose care to their kids and let them in charge of their medication. There is also a
huge problem with adolescent girls being infected. Lots of work is needed to address this issue
such as campaigns to keep them in school and to change laws on child marriage.
Q: Can you talk about the PMTCT efforts?
GM: With PMTCT, we hope to eliminate transmission but there will always be a trickle of kids
getting infected. We will never get it down to zero. Now with the B+ option, early antenatal tests
that are positive will immediately be put on ARVs (if the mother even goes to antenatal clinic).
When viral loads are lower, transmission is lower. We are now working with doctors in Liberia
so they can treat HIV themselves rather than referring patients to other doctors.
Q: How does co-infection with TB and HIV affect people?
GM: 1/3 of the population is infected with TB but not all show it and develop it. The TB
epidemic is at its peak in Africa. Here, it shows up and develops in this population more than in
higher-income countries, because they don’t have good sanitation or a stable health care
infrastructure. There is a ½ chance of developing TB in people with HIV because they have a
suppressed immunity system. TB thrives in these settings and the first killer of people with HIV
is TB.
With those who are TB diagnosed, the 1st line treatment is an intensive 2 months (which makes
patients feel a lot better) then a continuation for 4 months. However, if the patient defaults in 4
months, there is a nasty multi-drug resistance. There are not good TB drugs on the market as
well. More and more, we are finding HIV infected kids by them testing positive for TB. Pediatric
TB is a huge problem in Africa. How do we find these children? ½ of them will die before 2 but
we are not doing anything to find the other half that live. A solution could be implementing
vaccine programs through schools. Example: Juliana wasn’t diagnosed HIV positive and started
on ART until she was 10 years old!

Interview 2
Interviewee: Dr. Reuben Granich (RG) : Senior Advisor, Care and Treatment
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Location: Joint United Nations Program on HIV/AIDS (UNAIDS) Avenue Appia 20 1211,
Geneva 27
Date & Time: 07/11/14 at 10:00-11:00
Q: What is your job?
RG: I am an epidemiologist by training but I work as a tactician now. I am from the CDC and
have been secunded here. In 2009, my small group published an article in Lancelet. In the article,
we argued that if we tested and treated everyone in South Africa, we could eliminate HIV. This
was a modelling paper and ruptured the way people thought about treatment. Now, partly due to
this paper and others, treatment is not only seen as clinical but as a preventative measure. Your
lifespan is near normal when you are put on treatment. Before there are two camps, the testing
camp and the treatment camp—they usually worked in separate work streams. Everyone agrees
that it is important to get tested in order to know your status. In our paper, we combined the two
streams by exploring what would happen if everyone is tested and those who test positive would
be put on treatment immediately.
UNAIDS is a multilateral agency working on the global drive of the HIV response. They provide
leadership and manage resources.
Q: What are the limitations for pediatric HIV treatment in South Africa?
RG: I am not a pediatric ART expert, but I can see two main limitations. 1) Drug formulations
aren’t as refined for kids as they are for adults due to issues such as weight bands. 2) There are
delivery problems and perhaps the pediatric treatment guidelines make it too complex of a
system for treating kids. Just compare the guidelines for children and for adults; the pediatric
guidelines are probably more complex. There are also fewer studies involving children and the
main advocates for children are their parents.
Pediatric HIV treatment is also somewhat of a downstream approach. We must remember to also
focus on upstream interventions. If mothers never got infected, she would never transmit to her
kids. It is important to focus on treatment of adults and kids. Option B+ is more of an upstream
approach by encouraging all mothers to be on treatment. It was hugely controversial at first.
Malawi led the charge, and their initiative was widely successful from the start. Allowing access
to treatment for pregnant mothers is a three-for. It keeps the mother healthy, and prevents
transmission to their babies and their partners.
Q: Why do children have difficulty adhering to ARTs?
RG: Getting kids to take their medication is difficult. Formulations taste bad and there are a lot
to take. Poverty is also a huge issue. Scheduling monthly appointments at the clinic is really
difficult for the mothers to do. Often, clinics aren’t open long enough and there are longs lines as
mothers and children wait for appointments. We must work on designing a system that can reach
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everyone. In South Africa, you can’t do it all in the clinics. There aren’t enough resources for
everyone in need to get treatment at the same place every month. There are sociocultural issues
to deal with too such as disclosure problems and the stigma and discrimination around a positive
diagnosis.
Q: I was looking through the presentations on your dropbox and saw a graph showing that in
South Africa, pediatric ART coverage was around 48% while for adults it was around 40%. Why
is pediatric coverage higher than adult?
RG: Not sure without looking at the figures, but you also have to be careful of what is actually
being calculated. The way coverage is calculated changes when the WHO changes policies
regarding treatment. For example, in the past WHO eligibility for treatment was a CD4 count of
<200. Now that it is a CD4 count <500, the denominator of who is eligible changes. The real
picture is that 35 million people living with HIV will need treatment to remain healthy—without
treatment or they will die in 10 years. We have over 13 million on treatment but the remaining
people who are not on treatment have about a 10 year lifespan if they do not get treatment. In
other words, whether more kids or adults are getting treatment, there is still a large treatment gap
for both adults and children. Also there is a cascade. Of all the people with HIV, how many of
those know their status? Of those, how many are on ART? And of those, how many have viral
suppression? So in the end, what percentage is actually on treatment matters but what is most
important is the number of people who are on successful treatment for the long term.
Q: Is drug resistance testing such as genotypic testing an effective tool when deciding to switch
from first-line to second-line treatment?
RG: The problem is that this sort of testing is not available to a majority of the world. The tests
that are mainly used is the HIV antibody test which shows whether you have been exposed and
infected and the CD4 test which is a crude measure of the immune system. Genotype testing is
an expensive approach available in wealthier countries and research laboratories but a good one,
because when you know resistance patterns, you can tailor responses and treatments. There are
ethical considerations too. Do you provide genotype testing for kids or make sure everyone has
access to basic HIV and CD4 cell testing? Also, you have to look at what regimens you have. If
you only have one first line and one second line option, doing genotype testing may not help
since you have limited options to tailor the treatment regimen.
Q: South Africa’s national policies for pediatric HIV treatment are concurrent with the 2013
WHO Guidelines to commence ART irrespective of CD4 count. How will this improve ART
coverage for more children?
RG: The previous policies often translated into “test and wait”. Of course some children were
eligible but others were told to wait until they had further immune degradation. If you ask people
to wait then they may die or they could come back really sick, get on ART, and then die. People
from the community then may say “oh look, ART kills people.” It is probably a much better
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system now to start the kids right away on treatment. This new policies will expand the number
of children able to get treatment and provide support for them to adhere to their therapies. It will
also keep the children healthier as well.
Q: How closely to written policies reflect program implementation or clinical practice?
RG: Although some countries have already adapted their policy to the new science, others adapt
soon after WHO makes the change. Other countries wait for a while. To develop WHO policies
ia a 2-3 year process. It takes 2 years to develop the policies and then can take longer for some
countries to adapt to them. You also can’t assume that program implementation accurately
reflects the policy. When there are changes, governments make shifts and drive new responses
within the health system. But this can be a long time period for someone with HIV.
Q: What is the collaboration among UNAIDS and other organizations such as UNITAIDS, the
Global Fund, PEPFAR, and CHAI?
RG: It is a complex web of relationships. UNAIDS provides global leadership but also gets
funding from PEPFAR so this is a deep collaboration. . There is also a collaborative effort on
testing with UNITAID and around monitoring and modeling with CHAI. UNAIDS also works
closely with the Global Fund on efforts to fund the response. You could write books about the
relationship.
Q: What are the ethical considerations when dealing with HIV treatment among children?
RG: There are many. The main ethical issue usually revolves around the fact that in most places
children are less likely to get treatment than adults. Given that children rely on adults for
protection and treatment this is ethically wrong. The other ethical dilemma has to do with
resources. We have the resources to treat everyone, adults and children, to not do so raises
ethical issues. We also spend resources on trials and studies, some for children. These are
important but raise ethical issues—should some of these resources go towards treating children.
These are just some of the issues we are struggling with in our response.

Interview 3
Interviewees: Dudley Tarlton (DT): Program Specialist, Health and Development UNDP &
Fabien Lefrancois (FL): Policy Specialist, Partnership with the Global Fund UNDP
Location: 11-13 Chemin des Anémones, 1219 Châtelaine, Geneva, Switzerland
Date & Time: 13/11/14 at 11:00-11:45
Q: How does the UNDP operate within a country?
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FL: We have a partnership with the Global Fund (GF). In countries, we set up a co-PR modality.
We act as the interim recipient of the GF grant until the country is capable of managing the
funds. Procurement is not easily transferred, but it is a gradual process. You have to meet
milestones within a capacity development plan. You also need the resources to develop and
implement the grants. Then there is the policy environment where we promote an enabling
environment by working with the government. For instance, we assess barriers to access of
health (such as men who have sex with men in countries where this is illegal). The eligibility for
GP funding depends on income and disease burden. With a higher income, the more focused you
have to be on how you spend GF money. Yet the income of the country doesn’t necessarily paint
the picture for everyone there.
DT: UNDP doesn’t deal with the GF grants in South Africa but at a conference I was just at,
there was a video playing of the South African minister of health. He said that after looking
around and seeing that South Africa was paying more for HIV drugs than neighboring countries,
they negotiated price reductions for ARVs.
Q: How does the UNDP develop capacity in countries where it is acting as the interim grant
recipient?
DT & FL: We build capacity, then hand it over. We look at different functions to implement GF
grants and the status of those functions. Some of the functions are financial, risk management,
and MNE. We work with national partners, ministers of health etc. We are the principal
recipients of the GF grants but are not in charge of their entire implementation (work with
program management embedded in Ministries of Health).
Q: This is country-dependent but do you think the grants are used more for testing or for
treatment?
DT & FL: I would imagine more is spent on treatment. With testing, it’s not the amount of it but
who you test. A country can say they test a million people, but are they reaching the right
populations? So we have to target risk populations. There is a limited amount of money and it is
hard to scale up response when [WHO] guidelines change. The treatments must be sustainable
and now, testing and treatment are sort of being lumped together with the idea of treatment as
prevention.
Q: Does UNDP have a role in the HIV drug market?
DT: Not directly. UNICEF procures the medications for the UNDP.
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Interview 4
Interviewee: Lisa Nelson, MD (LN): Senior HIV Disease Advisor
Location: The Global Fund Chemin de Blandonnet 8 1214 Vernier-Geneva, Switzerland
Date & Time: 17/11/14 at 14:00-14:45
Q: What is a brief description of your job?
LN: I am a Senior HIV Disease Advisor. Part of my work is internal where we provide guidance
to the operation of the Global Fund (GF) grants and part of it is external where we work with
partners such as the WHO and UNICEF.
Q: I was looking at the website and saw there are 9 active Global Fund grants in South Africa
that deal with HIV/AIDS. Where does the money come from and how is it used?
LN: The GF was started in 2002 by Kofi Annan, former Secretary-General of the United
Nations. He saw a major gap in the funding. The GF is a multilateral agency with donors around
the world. The biggest donor countries are the United States and France. It started as a
performance based fund where countries has to compete for money but there is a new funding
model now where we look at the ability of a country to pay and their need. Also money is set
aside for each country until that country can submit a good application for a grant.
Q: Do any of these grants deal with pediatric HIV?
LN: The GF set up Country Coordinating Mechanisms (CCM) at country level. We recognize
that ministers of health and governments themselves are important in implementing the grants,
but we also want the targeted populations to have a role in implementation. The CCM proposes
what to do with the money, decides when to apply the grants, and decides who the principle
recipients of care are. 60% of the funds go to commodities (ARVs are so expensive).
Q: Is more grant money spent on testing or treatment?
LN: Treatment. The cheapest 1st line, for adults not kids, is still over $100 per patient per year.
That doesn’t seem like a lot but when you have thousands on treatment, it becomes millions of
dollars which is the bulk of the grant.
Q: How is the performance of a grant calculated? (How does one meet expectations?)
LN: When a country writes a grant, they include assessment models in their proposals. The new
funding model is that grants are 3 years long so countries are now applying for 2015, 2016 and
2017. There are regular check ins and progress reports. Performance is also monitored against
country targets set in the proposal.
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Q: How is access to ART increasing in South Africa?
LN: There has been a complete transformation in the way South Africa is dealing with HIV since
2009 when Jacob Zuma became President. The government is now doing more to broaden HIV
drug access to pregnant women and infants and to start ART sooner. Most of the treatment is
now funded by the government itself.
Q: Can you tell me about HIV drug resistance surveillance in South Africa?
LN: In the USA, if a person tests positive for HIV, you would check drug resistance to tailor a
treatment. But many countries lack the resources to provide this. South Africa is somewhere in
the middle, because it has higher lab capacity than neighboring countries and it might even have
private clinics. The WHO has recommendations to do periodic drug resistance surveys with
representative populations.
Q: Is HIV drug resistance (genotypic) testing cost-effective? If not, can it be in the future?
LN: At the moment, it is not feasible to do for each patient. The drug supply chain is fragile and
so are health care systems. Everyone gets the standard first line treatment. But even if genotypic
testing was cost effective, it would be hard to operationalize all these systems and changes. One
hopes there will be a dip stick test (a low cost strategy) for drug resistant HIV to identify
mutations. There has been success with TB. The gene expert test detects TB and Rifampicin (the
main drug used) resistance. It isn’t exactly point of care because it uses electricity but it could be
used in the rural setting to test right there. Of course it is still relatively expensive and not
available everywhere but with this, a patient can come in, get tested, and be put on a treatment
that they will respond well to.
Q: How can we reduce HIV drug resistance among infants and children?
LN: You start with the general population. We know poor adherence is a major factor. There
needs to be better treatment options. Right now, formulations for children are hard to take, are in
liquid form, and must be taken multiple times per day. Since the PMTCT strategies have
increased, more people are on ART so naturally drug resistance will increase. Also before
recently, single-dose nevirapine was used and using one drug is a good way to get drug
resistance. Now we are going to combination formulations for PMTCT. Before, drugs were less
potent and we would say we needed 95% adherence which is really difficult. With drugs being
more potent now, they are more forgiving in regards to resistance and we can have a lower
percent of adherence. There is also viral load monitoring. WHO recommends monitoring to
identify failure quickly. If failure is not found quickly, it will amplify the resistance.
Q: Do you think increasing media efforts and education on HIV would improve adherence for
children?
LN: I don’t know if mass media efforts will do that much because people think that it doesn’t
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apply to them. We do know that peer support is very important and so is working with
communities. With children, it is harder to hide that they are on ART and harder to hide their
status which is a reason why mothers don’t get their children tested.
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